Who are Revex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Korsuva, Remitch, Halflytely, Stadol Preservative Free, Codeine, MS Contin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nalmefene.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Revex — Competitive Intelligence Brief

Revex (NALMEFENE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid Antagonist. Area: Neuroscience.

marketed Opioid Antagonist Kappa-type opioid receptor Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Revex (NALMEFENE) — Hikma.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Revex TARGET	NALMEFENE	Hikma	marketed	Opioid Antagonist	Kappa-type opioid receptor	1995-01-01
Korsuva	DIFELIKEFALIN	Vifor Intl	marketed	Kappa Opioid Receptor Agonist	Kappa-type opioid receptor	2021-01-01
Remitch	NALFURAFINE		marketed	nalfurafine	Kappa-type opioid receptor	2009-01-01
Halflytely	BISACODYL	Braintree	marketed	Stimulant Laxative [EPC]	Kappa-type opioid receptor	2004-01-01
Stadol Preservative Free	BUTORPHANOL		marketed	Opioid Agonist/Antagonist	Kappa-type opioid receptor	1978-01-01
Codeine	codeine phosphate	Generic (multiple manufacturers)	marketed	Opioid analgesic, Antitussive	Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor	1950-01-01
MS Contin	morphine sulfate	Generic (multiple manufacturers)	marketed	Opioid analgesic	Solute carrier family 22 member 1, Delta-type opioid receptor, Kappa-type opioid receptor	1941-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-08-12 — MS Contin · 7955619 · Formulation · US
2028-08-12 — MS Contin · 10314788 · Formulation · US
2033-07-01 — MS Contin · 9044402 · Formulation · US
2033-07-01 — MS Contin · 9549899 · Formulation · US
2034-03-12 — MS Contin · 9248229 · Formulation · US
2034-03-12 — MS Contin · 9192608 · Method of Use · US
2034-03-12 — MS Contin · 9072781 · Formulation · US

Sponsor landscape (Opioid Antagonist class)

Adapt · 1 drug in this class
Averitas · 1 drug in this class
Bdsi · 1 drug in this class
Cubist Pharms · 1 drug in this class
Hikma · 1 drug in this class
Salix Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Revex — Competitive Intelligence Brief. https://druglandscape.com/ci/nalmefene. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab